InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
6
T+90 hit rate
73%
T+90 mean return
+5.2%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by LYONS GARY A, Director. Director active across 4 companies, notably Travere Therapeutics, Inc.. Cumulatively, 27 reports have been published. Split: 0 buy · 6 sells. Total volume traded: €4.3m. Activity tracked since 14 May 2021. The latest transaction was disclosed on 22 May 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations27 total
1,435 shares0Common StockSEC:0000914475-25-000127:0
6,500 shares0Common StockSEC:0001415889-25-013499:0
40,000 shares@ US$10.48100.0% of flowCommon StockSEC:0001415889-24-024795:0
11,570 shares@ US$42.767.8% of flowCommon StockSEC:0000914475-24-000195:0
930 shares@ US$42.760.6% of flowCommon StockSEC:0000914475-24-000172:0
2,100 shares0Common StockSEC:0000914475-24-000129:0
12,500 shares@ US$42.768.6% of flowCommon StockSEC:0000914475-24-000123:0
6,500 shares0Common StockSEC:0001415889-24-012847:0
10,000 shares@ US$130.044320.6% of flowCommon StockSEC:0001209191-23-059771:0
5,000 shares@ US$12.981.0% of flowCommon StockSEC:0000914475-23-000080:0
5,000 shares@ US$12.981.1% of flowCommon StockSEC:0001209191-23-049448:0
5,000 shares@ US$12.981.0% of flowCommon StockSEC:0001209191-23-048383:0
25,000 shares0Common StockSEC:0001140361-23-034287:0
4,500 shares0Common StockSEC:0001209191-23-030959:0
15,000 shares@ US$12.713.3% of flowCommon StockSEC:0001209191-22-055393:0
5,000 shares@ US$110.54229.6% of flowCommon StockSEC:0001209191-22-052894:0
25,000 shares0Common StockSEC:0001140361-22-020305:0
3,000 shares0Common StockSEC:0001209191-22-028694:0
15,000 shares@ US$6.660.0007% mcap3.5% of flowCommon StockSEC:0001209191-22-025824:0
5,000 shares@ US$105.05870.0032% mcap17.2% of flowCommon StockSEC:0001209191-21-060283:0
5,000 shares@ US$105.05877.9% of flowCommon StockSEC:0001209191-21-060283
10,000 shares@ US$100.274314.4% of flowCommon StockSEC:0001209191-21-040445
10,000 shares@ US$100.27430.0058% mcap31.1% of flowCommon StockSEC:0001209191-21-040445:0
25,000 shares0Common StockSEC:0001179110-21-005765
25,000 shares0Common StockSEC:0001179110-21-005765:0
25 of 27 declarations
About LYONS GARY A
Gary A. Lyons is a Director at Travere Therapeutics, Inc. and RIGEL PHARMACEUTICALS INC. In these roles, he contributes to the governance and strategy of the companies. His expertise in the pharmaceutical sector is essential for their development.
